TickerFacts.

Biolife Solutions Inc (BLFS): Cost of Revenue

Annual figures by period end, from SEC filings.

$34.10M
Year ended 2025-12-31
$38.82M
Trailing 12 months to 2026-06-30
2023-12-31: $26.70M2024-12-31: $24.55M2025-12-31: $34.10M$34.10M
2023-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$34.10M+38.9%2026-02-26, From 2025-01-01
2024-12-31$24.55M-8.0%2026-02-26, From 2024-01-01
2023-12-31$26.70Mn/a2026-02-26, From 2023-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Electromedical & Electrotherapeutic Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Biolife Solutions Inc (BLFS)2025-12-31$34.10M+38.9%
Vaso Corp (VASO)2025-12-31$34.42M-0.8%
Ceribell, Inc. (CBLL)2025-12-31$10.79M+24.1%
Outset Medical, Inc. (OM)2025-12-31$72.72M-3.2%
Electromed, Inc. (ELMD)2026-06-30$15.83M+12.9%
Iridex Corp (IRIX)2026-01-03$33.45M+14.7%
Axogen, Inc. (AXGN)2025-12-31$57.85M+27.5%
Stereotaxis, Inc. (STXS)2025-12-31$15.31M+24.2%
electroCore, Inc. (ECOR)2025-12-31$4.24M+12.1%

Compare BLFS, VASO, CBLL, OM side by side · Screen every company in Electromedical & Electrotherapeutic Apparatus ↗